Indaptus Therapeutics, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. The company is a clinical-stage biotechnology company developing Decoy20, an investigational immunotherapy. It has no approved products and has generated no product revenue.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | None reported; no product sales | |||
| Research and development expense | $2.23 million | $1.61 million | $5.59 million | $4.41 million |
| General and administrative expense | $2.02 million | $1.94 million | $6.61 million | $6.41 million |
| Total operating expenses | $4.25 million | $3.55 million | $12.20 million | $10.82 million |
| Net loss | $3.92 million | $3.47 million | $11.42 million | $10.67 million |
| Net loss per share, basic and diluted | $0.47 | $0.42 | $1.36 | $1.29 |
As of September 30, 2023, cash and cash equivalents were $15.96 million, versus $9.63 million at year-end 2022. Marketable securities were zero, down from $16.81 million; their maturities and reinvestment contributed to the cash balance change. Current assets were $16.84 million and current liabilities $2.37 million, implying working capital of approximately $14.48 million. Total liabilities were $2.46 million, principally payables and operating lease liabilities; the filing reports no borrowings.
Operating cash use was $10.80 million for the first nine months, compared with $10.87 million in 2022. Investing activities provided $17.14 million, mainly from $24.0 million of marketable-security maturities, partly offset by $6.86 million of purchases. There was no financing cash flow. Operating margins are not meaningful because the company had no revenue.
Changes versus the comparable period
- Q3 operating expenses rose 20%; R&D increased 38%, primarily with the Phase 1 trial and pipeline work. Nine-month operating expenses rose 13%, with R&D up 27%.
- Net loss increased 13% in Q3 and 7% for the nine-month period. Higher interest income partly offset operating costs: nine-month other income rose to $778,000 from $157,000.
- Cash and cash equivalents increased from year-end, while marketable securities were converted to cash. Stockholders’ equity declined to $15.33 million from $24.63 million, reflecting accumulated losses.
Outlook, development, and risks
- Management estimated that available cash would fund operations into the second quarter of 2024 under its current plan. The company expects significant ongoing losses and cash outflows and concluded that substantial doubt exists about its ability to continue as a going concern within one year after filing.
- Management plans to seek funding through collaborations, strategic alliances or licenses, and/or debt or equity financing. There is no assurance funding will be available on acceptable terms. Failure to secure capital could force the company to delay, reduce or end research programs or cease operations; equity financing could dilute shareholders.
- Decoy20 Phase 1 trial: the first single-dose cohort was completed in August 2023, with four patients evaluable. Reported symptoms or adverse events were short-lived and consistent with the product’s mechanism of action. The company advanced to a second, lower-dose cohort in September following Safety Review Committee authorization; management cited the first cohort’s pharmacodynamic effect and anticipated safety profile. Dose-finding data are expected to inform a recommended Phase 2 dose; multi-dose and combination studies were planned for 2024.
- Management expected R&D and G&A expenses to increase as clinical development progresses and the company supports operations. Clinical results, enrollment, regulatory review, third-party manufacturing and research providers, and access to capital are major uncertainties.
- The company amended its office lease through October 2025. Future minimum payments were approximately $214,000. The prior LTS arbitration dispute was settled in February 2023; the filing reports no pending material legal proceedings. Management stated disclosure controls were effective at the reasonable-assurance level and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Cash runway assumptions and whether the company has obtained financing or partnerships since the November 6, 2023 filing date.
- Decoy20 trial enrollment, safety findings, dose-selection rationale, and timing of planned multi-dose or combination studies.
- Availability and terms of potential financing, including dilution and the status of the Lincoln Park purchase agreement. No shares had been sold under that agreement as of the filing.
- The available capacity under the ATM program: the filing describes up to $6.3 million in one section and $3.7 million in a risk-factor discussion; the text does not reconcile these figures.
- Potential dilution: 8,401,047 common shares were outstanding; the filing also reports 2,050,197 options and warrants to purchase 3,090,787 shares, generally excluded from diluted loss per share as anti-dilutive.